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Abstract
Aim To summarize findings from studies reporting the prevalence and incidence of diabetic retinopathy and diabetic maculopathy
in African countries in light of the rising prevalence of diabetes mellitus.
Methods Using a predefined search strategy, we systematically searched MEDLINE, EMBASE, Science Citation index and
Conference Proceedings Citation index, African Index Medicus and the grey literature database ‘OpenSIGLE’ for studies published
between January 1990 and February 2011. Included studies reported prevalence or incidence of diabetic retinopathy or diabetic
maculopathy of subjects with diabetes resident in African countries.
Results Sixty-two studies from 21 countries were included: three population-based surveys; two cohort studies; five case–control
studies; 32 diabetes clinic-based, nine eye clinic-based and 11 other hospital-based surveys. Included studies varied considerably in
terms of patient selection, method of assessing the eye and retinopathy classification. In population-based studies, the reported
prevalence range in patients with diabetes for diabetic retinopathy was 30.2 to 31.6%, proliferative diabetic retinopathy 0.9 to
1.3%, and any maculopathy 1.2 to 4.5%. In diabetes clinic-based surveys, the reported prevalence range for diabetic retinopathy
was 7.0 to 62.4%, proliferative diabetic retinopathy 0 to 6.9%, and any maculopathy 1.2 to 31.1%. No obvious association
between prevalence and income level of the country was detected.
Conclusions Large, community-based cross-sectional and cohort studies are needed to investigate rates and determinants of
prevalence of diabetic retinopathy, incidence and progression in Africa. Consensus is needed on the most appropriate methods of
identification and classification of retinopathy for research and clinical practice. Estimates of prevalence of diabetic retinopathy,
proliferative diabetic retinopathy and maculopathy are comparable with recent European and American studies.
Diabet. Med. 30, 399–412 (2013)
Introduction
The International Diabetes Federation (IDF) has estimated that
the number of adults with diabetes in Africa will expand by
98%, from 12.1 million in 2010 to 23Æ9 million in 2030 [1]—a
consequence of urbanization, sedentary lifestyles, obesity, and
population growth and ageing (in part as a result of successes in
combating communicable diseases) [2]. Thirty-one of the 48
least economically developed countries, as defined by the Uni-
ted Nations, are situated in Africa [3]. The epidemic rise in
diabetes therefore poses significant public health and socio-
economic challenges for the continent.
Diabetes causes visual impairment through cataract and dia-
betic retinopathy, a progressive disease of the retinal microvas-
culature. Diabetic retinopathy can be broadly divided into two
clinical categories: non-proliferative and proliferative diabetic
retinopathy. The pathophysiology of non-proliferative diabetic
retinopathy is characterized by abnormal permeability of retinal
capillaries leading to retinal oedema, and closure of capillaries
leading to retinal non-perfusion and ischaemia. Diabetic mac-
ulopathy occurs when these processes affect the macula and are
therefore a threat to visual functioning. Clinically significant
macular oedema (CSMO) is a term from the Early Treatment of
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Diabetic Retinopathy Study (ETDRS) [4] and is an evidence-
based threshold for laser photocoagulation treatment.
Proliferative diabetic retinopathy occurs when retinal
ischaemia is sufficiently severe to lead to the formation of new
vessels. Visual loss occurs in proliferative diabetic retinopathy
when these vessels bleed, or tractional retinal detachment
ensues from fibrovascular proliferation. Without treatment,
50% of patients with proliferative diabetic retinopathy will
become blind within 5 years [5]. Diabetic retinopathy can be
graded on the basis of the clinical features. The grades of
retinopathy correlate with likelihood of development of
proliferative diabetic retinopathy and can be standardized by
standard retinal photographs, as used in the Early Treatment of
Diabetic Retinopathy Study [4]. The aim of this systematic
review was to summarize findings from reliable research studies
of estimates of the prevalence and incidence of diabetic
retinopathy and maculopathy in African countries.
Methods
Data sources and search strategy
A systematic narrative review of published literature was
performed according to the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) statement [6].
Relevant studies published between 1948 and February 2011
were identified by searching, using a predefined strategy, the
following electronic databases:MEDLINE (PubMed), EMBASE
(OVID) and EMBASE Classic, Science Citation index and
Conference ProceedingsCitation index (ISIWebof Science). The
following were also searched: the African regional database
‘African Index Medicus’, the grey literature database ‘Open-
SIGLE’, the World Health Organization (WHO) International
Clinical Trials Registry and the meta-Register of Controlled
Trials (mRCT). Customized searches were developed by one of
the authors (PIB) in conjunctionwith aCochraneCollaboration-
trained trials coordinator. Search histories are reproduced in the
Supporting Information (Appendix S1). No language, publica-
tion status, time limits or language restrictions were applied to
electronic searches. Search results were merged using reference
management software (Endnote, Thomson Reuters) and dupli-
cate records removed. The reference lists of articles identified,
including existing reviews, were hand-searched.
Selection criteria
The following were included: studies reporting prevalence or
incidence or progression of diabetic retinopathy or diabetic
maculopathy; cross-sectional or cohort study design; studies of
subjects with diabetes mellitus resident in African countries.
Exclusion criteria were: studies with fewer than 50 subjects;
studies of populations of African origin residing outside the
continent; reports not published in English; case series and
conference abstracts. To improve the current relevance of the
review those reports published before 1990 were excluded.
The method used to apply selection criteria was as follows.
Titles and abstracts were examined by one investigator (PIB)
and obviously irrelevant reports removed. Full text copies of
the potentially relevant reports were retrieved. Multiple reports
of the same study were linked together. Full-text reports were
examined independently by two investigators (PIB and IJCM)
for compliance with eligibility criteria. Disagreements were
resolved by discussion.
Data extraction and assessment of risk of bias
Major outcome variables were extracted independently by two
investigators (PIB and IJCM) into a spreadsheet (Excel,
Microsoft) with a standardized approach. Any disagreement
was resolved by discussion. The main outcome variables
extracted were the prevalence of diabetic retinopathy, prolif-
erative diabetic retinopathy and diabetic maculopathy and the
incidence of diabetic retinopathy, proliferative diabetic reti-
nopathy and diabetic maculopathy. Prevalence of grades of
retinopathy were recorded by patient according to the worse
eye and, unless stated, are presented as such below. Studies
were stratified by the source of the population sample (with
community studies more likely to give a more accurate popu-
lation-based assessment of prevalence); and risk of bias was
assessed by seeking evidence of incomplete outcome data
(missing data, patients excluded from report, patients lost to
follow-up in cohort studies).
Results
The literature search yielded 380 citations, of which 142 were
reviewed in full text; 71 met the inclusion criteria and reported
on a total of 62 studies (Fig. 1) [7–60], and see also Supporting
Information (Appendix S2 [82–98]). Literature search report
reproduced in the Supporting Information (Table S1).
Characteristics of included studies
Characteristics of the included studies are summarized in the
Supporting Information (Table S2).
Design
Only three community-based studies were identified [7–9]. In
Mauritius, in 1998, researchers followed up the population-
based study performed in 1992 [7] with a survey of the same
cohort 6 years later [10]. An additional cohort study followed a
group of patients with Type 1 diabetes identified from a hospital
clinic [11–13].Allother studieswereclinic-basedsurveysorcase–
control studies; the majority were undertaken in diabetes clinics
(hospital or primary care) or hospital ophthalmology clinics.
Distribution
The 62 studies were performed in 21 countries. Geographical
distribution of studies was uneven and, within geographical
regions, certain countries were over-represented. All of 19
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studies undertaken in Western Africa took place in Nigeria,
except one that covered Nigeria and Ghana [14] and one from
Mali [15]. Within East Africa, two studies were conducted in
the Seychelles [16,17] and two in Mauritius [7,10]: relatively
wealthy, ethnically diverse, small island nations. There was no
clear correlation between the average standard of living in a
country, as measured by per capita gross domestic product
(GDP) and reported prevalence of diabetic retinopathy (Fig. 2)
or proliferative diabetic retinopathy (see also Supporting
Information, Fig. S1). Only five studies specifically reported
data from rural populations [7–9,18,19].
Patient selection
Clinic-based studies were highly heterogeneous in patient
selection in relation to age range, gender, ethnicity, duration
and type of diabetes and co-morbidity. Of those studies
conducted in diabetes clinics, 18 included all patients with
diabetes attending the clinic, while 14 confined their study to
a subgroup; for example, subjects with Type 2 diabetes [20],
children 5–18 years [21] or patients with duration of diabe-
tes > 5 years [22]. Of the nine studies conducted in oph-
thalmology clinics, four studied patients with a particular
diagnosis (neovascular glaucoma [23], retinal disease [24,25],
blindness [26]), one studied patients attending specific dia-
betes eye clinics [17] and four studied a cross section of all
eye patients [27–30]. In those studies that differentiated
Type 1 and Type 2 diabetes (30 studies), most used study-
specific definitions, making inter-study comparisons prob-
lematic.
Assessment of retinopathy
Methods of assessment and classification of retinopathy varied
widely. Only nine studies used retinal photography [7,10,31–
37] and six of these were conducted in South Africa [31–33,35–
37]. Thirty studies classified retinopathy simply as present or
absent; 32 used a recognized grading system. Most used an
adaptation of the Early Treatment of Diabetic Retinopathy
Study grading system [4]. However, the application and its
reporting varied widely. In no study was an external validation
of the practitioner’s grading reported.
Id
en
ti
fic
at
io
n
4 additional records
identified through other
sources
380 records after
duplicates removed
Sc
re
en
in
g
238 records excluded380 abstracts screened
El
ig
ib
ili
ty 71 full-text articles excluded:
11 review articles
25 did not report diabetic
retinopathy prevalence
3 not English language
32 published before 1990
142 full-text articles assessed
for eligibility
In
cl
ud
ed 62 studies included in the
review (from 71 articles)
742 records identified
through database
searching
FIGURE 1 Identification process for eligible studies. Format reproduced from the PRISMA statement [6].
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Evidence of bias
There was evidence of incomplete outcome data in a number of
studies. In the majority of clinic-based studies, the number of
patients approached to participate was not reported, making
selection bias difficult to assess. Many studies reported preva-
lence of a number of diabetic complications. In some studies, a
low proportion of patients were examined for retinopathy. For
example, in Harzallah et al. [38] only 19% of 593 patients
underwent retinal examination. Many studies excluded patients
with significant cornea or media opacities [39,40] or with
ungradeable photographs [31].
Community-based studies
We identified three community-based studies (Table 1). In
Egypt, in 1991–1994, researchers examined the prevalence of
diabetes and the relationship between HbA1c and retinopathy
[8,34,41,42]. Articles by Herman et al. [34] and Penman et al.
[41] report different prevalence of diabetic retinopathy as gra-
ded from retinal photography: 35.4% in 376 subjects in the
former and 31.6% in 335 subjects in the latter. No explanation
for this difference between the two reports is offered, suggesting
missing data in one or both analyses. Herman et al. [34]
demonstrated in multivariate analysis that diabetic retinopathy
was associated with longer duration of diabetes (per 10 years)
(odds ratio = 1.37, 95% CI 1.09–1.73) and higher HbA1c (per
unit) (odds ratio = 1.15, 95% CI 1.03–1.27).
In 1992, researchers in Mauritius [7] investigated prevalence
of and risk factors for diabetic retinopathy in Asian Indian,
Chinese and Creole Mauritians. This high-quality study dem-
onstrated a high prevalence of diabetic retinopathy in all major
ethnic groups in Mauritius. The prevalence of diabetic reti-
nopathy and proliferative diabetic retinopathy were particu-
larly high in known diabetes: 44.3 and 2.3%, respectively.
Muslim Indians had the lowest prevalence of retinopathy (10.8
and 34.0% for new and known diabetes, respectively); signif-
icantly lower than Creoles (18.8 and 53.8%, respectively). The
following were independently associated with retinopathy:
duration of diabetes, fasting plasma glucose, systolic blood
pressure, albuminuria and decreasing BMI.
Cohort studies
Table 2 summarizes cohort studies of diabetic retinopathy
conducted in Africa. In Mauritius, in 1998, researchers fol-
lowed up the population-based study performed in 1992 [7]
with a survey of diabetes complications [10]. Of subjects with
diabetes in the initial survey, 40.5% were re-examined. The
6-year incidence of diabetic retinopathy and proliferative
diabetic retinopathy in subjects with diabetes but no diabetic
retinopathy in the first survey was 23.8 and 0.4%, respectively.
The incidence of proliferative diabetic retinopathy was
much higher in subjects with mild non-proliferative diabetic
retinopathy (5.2%) and moderate non-proliferative diabetic
retinopathy (29.4%) in the first survey. Duration of diabetes
and fasting blood glucose were independently associated with
incidence of retinopathy. In South Africa, in 1982–2002, Gill
and co-workers identified a cohort of patients with diabetes
requiring insulin therapy diagnosed before age 30 years [11].
In those subjects seen at 10 years, prevalence of diabetic
retinopathy had increased from 6 to 52% and proliferative
diabetic retinopathy from 0 to 3% [12]. In subjects seen at
20 years, prevalence of diabetic retinopathy had increased from
12 to 59% [13].
No other prospective cohort studies were identified. How-
ever, studies reflecting cumulative incidence of diabetic reti-
nopathy are available. In South Africa, Distiller et al. [32]
reported on 1520 patients with Type 1 diabetes and 8026
patients with Type 2 who had maintained membership for
‡ 5 years of a community-based, privately funded diabetes
management programme. In subjects with Type 1 diabetes,
prevalence of any retinopathy at baseline and at 5 years was
22.3 and 28%, respectively, and in subjects with Type 2
diabetes was 20.5 and 26.6%, respectively. In retrospective
studies of patients with diabetes of long duration, Lester [43]
showed a prevalence of diabetic retinopathy of 45.5% in 121
Ethiopian patients with duration of diabetes > 20 years, while
Distiller et al. [33] reported presence of diabetic retinopathy in
14.8% of 148 South African Caucasian patients with Type 1
diabetes of > 18 years duration.
Hospital-based and primary care-based surveys
Tables 3, 4 and 5 summarize hospital-based and primary care-
based surveys reporting prevalence of diabetic retinopathy
using a recognized grading system. The most recent large study
from Northern Africa was conducted in Cairo during 2007–
2008 in endocrinology clinics in two major teaching hospitals
[39]. Prevalence of proliferative diabetic retinopathy (2.3%)
and clinically significant macular oedema (11.5%) reported in
this study was high. Of four studies from Western Africa [44–
47], none reported the prevalence of maculopathy (Table 3).
FIGURE 2 Prevalence of diabetic retinopathy in patients with diabetes
according to national per capita gross domestic product. Red markers:
population-based studies. Blue markers: cohort and clinic-based studies.
For cohort studies prevalence in baseline survey shown. Gross domestic
product per capita figures: International Monetary Fund (2011) [79].
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Only three were identified from Middle Africa [22,48,49].
Longo-Mbenza et al. [48] studied 3010 patients with diabetes
attending diabetes primary care facilities using retinal photog-
raphy; prevalence of diabetic retinopathy was 31.6%.
Hospital-based surveys from Eastern Africa cover nine
countries showing a general trend of increasing prevalence of
diabetic retinopathy from earlier to more recent studies (Ta-
ble 4). Diabetes clinic-based surveys from Southern Africa in
general report higher prevalence of diabetic retinopathy and
proliferative diabetic retinopathy than comparable clinics in
other regions of Africa (Table 5). Proliferative diabetic reti-
nopathy prevalence > 4% was recorded in three studies of
unselected diabetes clinic attendees from South Africa
[19,36,50]. Data on prevalence of diabetic maculopathy were
limited from all regions. However, eight studies suggest high
prevalence [17,19,25,36,39,50–52]. Of note, three South Afri-
can, primary care-based studies were identified. Levitt et al.
[50], Mash et al. [36] and Read and Cook [51] reported high
prevalence of proliferative diabetic retinopathy and maculop-
athy (Table 5), comparable with hospital-based surveys in the
same country and higher than hospital-based surveys elsewhere
in Africa.
Two studies from South Africa compared prevalence of
diabetic retinopathy in different ethnic groups [35,51]. The
authors acknowledge the effect of environmental factors on
different racial communities, even in the post-apartheid era.
Kalk et al. [35] studied 507 ‘poor or indigent’ patients
attending a free hospital diabetes clinic. Prevalence of diabetic
retinopathy was similar in patients of African (37%), European
(41%) or Indian (37%) heritage. However, ‘severe diabetic
retinopathy’ (study-specific classification) was significantly
more frequent in Africans (52%) and Indians (41%) compared
with Europeans (26%). Read and Cook [51] found no rela-
tionship between ethnicity and diabetic retinopathy prevalence.
Studies reporting visual acuity
Nineteen studies reported visual acuity in subjects with diabe-
tes; parameters reported varied widely between studies. Only
the Nigerian national blindness and visual impairment survey
[9] tested logarithm of the minimum angle of resolution (log-
MAR) acuity. The population-based Mauritius diabetes com-
plication study [7] reported best-corrected visual acuity < 6 ⁄12
in 7.1% of subjects with diabetes at baseline. There was no
difference in this figure for subjects with and without retinop-
athy. The Diabetes in Egypt project [41] reported visual acuity
in 427 subjects with diabetes. Of these, 31 (7.3%) were blind
(defined as best-corrected visual acuity in the better eye less
than 6 ⁄60); 239 (56%) had a best-corrected visual acuity
between 6 ⁄12 and 6 ⁄60. It is likely that media opacities
accounted for a proportion of this visual impairment: 123 eyes
had cataract; 11 had corneal opacity; 17 had both.
The Nigerian national blindness and visual impairment sur-
vey was conducted between 2005 and 2007 [9]. Diabetic reti-
nopathy was identified as the primary cause of visual
impairment in 0.29% of 3129 subjects with uncorrected visual
acuity worse than 6 ⁄12 and in 0.5% of those with acuity less
than 3 ⁄60. This study is likely to underestimate the visual
impact of diabetic retinopathy as examiners were instructed to
preferentially record treatable, then preventable causes of visual
impairment; i.e. cataract would be recorded in preference to
diabetic retinopathy if both were affecting visual acuity to
similar degrees.
Discussion
This systematic narrative review describes 62 studies reporting
the prevalence and incidence of diabetic retinopathy and
maculopathy in Africa. The methodological approach used
standard inclusion, appraisal and data extraction approaches.
Few high-quality, population-based studies were identified: the
majority of studies were surveys of hospital clinic attendees.
Identified studies were highly heterogeneous in terms of patient
selection and method of assessment and classification of reti-
nopathy. Despite these inconsistencies between studies, the
review identified rates of prevalence of diabetic retinopathy in
many areas of Africa comparable with high-income countries.
Prevalence of proliferative diabetic retinopathy and maculop-
athy was high in recent studies, particularly those from
Southern and Eastern Africa. Common themes were identified
in the associations of diabetic retinopathy and impact on vision.
Methodology of included studies
The review identified three high-quality, population-based,
cross-sectional studies of diabetic retinopathy epidemiology [7–
9]. Only two cohort studies were identified. Large epidemio-
logical studies are expensive; the population-based studies were
conducted in states with relatively greater resources: Nigeria,
Mauritius and Egypt. The lack of studies fromMiddle Africa is
likely to reflect lack of resources, poor health infrastructure and
deficiency of trained medical professionals. The relatively small
number of studies identified from Northern Africa is partially
explained by the tendency of francophone countries to publish
in French.
The literature is dominated by studies of urban populations
reflecting the distribution of major health facilities. Urbaniza-
tion is seen as an important factor driving the diabetes epidemic
[61]; studies of urban populations may overestimate diabetic
retinopathy prevalence. A caveat is that, in resource-poor set-
tings, patients travel long distances to health facilities and rural
patients may therefore be included. The majority of studies
identified were hospital clinic-based surveys; selection bias is a
major issue and the findings should be generalized to other
settings with caution. Another bias is that clinics are seen by
many as a point to collect medication; patients with diet-con-
trolled diabetes may be under-represented. The classification of
diabetes in Africa is problematic, particularly where investiga-
tions are limited. Disease characteristics differ from Caucasian
populations. For example, peak age of onset of Type 1 diabetes
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is later in African communities, typically 22–29 years [62].
Other phenotypes of diabetes are recognized in patients of
African origin, including ‘atypical African diabetes’ and ‘mal-
nutrition-related diabetes’ [63].
Adaptations of the Early Treatment of Diabetic Retinopathy
Study grading system have become the accepted reference stan-
dard for classifying retinopathy in research settings. Despite this,
its use in everyday clinical practice is difficult because of a large
number of levels requiring correlations with standard photo-
graphs and grading rules that must be remembered. General
ophthalmologists and physicians in resource-poor settings may
not be able touse this system to a reproducible level. Stereoscopic
photography with validated grading is rapidly becoming the
reference standard for assessing retinopathy. Digital photogra-
phy allows transfer of images to distant reading centres, as was
used in the Diabetes in Egypt project [8,34,41,42]. While
expensive, this may be the direction of future research.
Prevalence and incidence of diabetic retinopathy and diabetic
maculopathy
Community-based studies identified in this review reported
prevalence rates of diabetic retinopathy and proliferative
diabetic retinopathy comparable with American and European
populations with diabetes. The Diabetes in Egypt project
[8,34,41,42] reported a prevalence of diabetic retinopathy and
proliferative diabetic retinopathy in subjects with diabetes of
31.6 and 0.9%, respectively. The Mauritius diabetes complica-
tion study [7] reported 30.2% diabetic retinopathy and 1.3%
proliferative diabetic retinopathy; the prevalence of proliferative
diabetic retinopathy in subjects with known diabetes was 2.3%.
In comparison, a 2005–2008 cross-sectional sample of US adults
with diabetes aged 40 years and older estimated prevalence of
diabetic retinopathy and proliferative diabetic retinopathy as
28.5% and 1.5%, respectively [64]. Recent population-based
studies in Europe have reported similar rates [65–69]. Younis
et al. [65] studied 8062 patients with diabetes entering an
English primary care-based screening programme. The preva-
lences of any retinopathy and proliferative diabetic retinopathy
in Type 1 diabetes were 45.7 and 3.7%, respectively, and in
Type 2 diabetes were 25.3 and 0.5%, respectively.
The lack of community-based studies from Sub-Saharan
Africa is important. Very high prevalence of diabetic retinop-
athy, proliferative diabetic retinopathy and maculopathy has
been reported in notable high-quality, clinic-based surveys in
the last decade: in Eastern Africa by Glover et al. [52] (32.0%
diabetic retinopathy, 5.7% proliferative diabetic retinopathy,
15% sight-threatening maculopathy), and in South Africa by
Mash et al. [36] (62.4% diabetic retinopathy, 6.1% prolifera-
tive diabetic retinopathy, 15.2% any maculopathy) and
Rotchford and Rotchford [19] (40.3% diabetic retinopathy,
5.6% proliferative diabetic retinopathy, 10.3% clinically sig-
nificant macular oedema). These figures are likely to reflect
factors including ethnicity, poor access to medical services, late
diagnosis, and co-pathology including infection (importantly
HIV and malaria), hypertension, malnutrition, and anaemia.
We found no clear relationship between per capita gross
domestic product and prevalence of diabetic retinopathy or
proliferative diabetic retinopathy. However, the increased
infrastructure to detect disease in states with greater resources is
an important confounding factor.
The influence of ethnicity on diabetic retinopathy prevalence
in populations of African origin has yet to be determined. In the
USA, Zhang et al. [64] reported prevalence of both diabetic
retinopathy and vision-threatening retinopathy (defined as
Early Treatment of Diabetic Retinopathy Study severe non-
proliferative diabetic retinopathy, proliferative diabetic reti-
nopathy, or clinically significant macular oedema) to be higher
in non-Hispanic black subjects (38.8 and 9.3%, respectively)
compared with non-Hispanic white subjects (26.4 and 3.2%,
respectively). Previous studies have shown similar results
[70,71]. However, differences were attributable to risk factors
for retinopathy [71]. Therefore, while associations between
polymorphisms of specific genes and diabetic retinopathy have
been described in African populations [72], no ethnic propen-
sity to retinopathy has been identified.
Neither of the two cohort studies identified by this review
reported two- or three-step progression on the Early Treatment
of Diabetic Retinopathy Study scale, as used in recent European
studies [73]. The Mauritius diabetes complication study [10]
reported 6-year incidence of diabetic retinopathy (23.8%).
Six-year progression to proliferative diabetic retinopathy was
reported from no diabetic retinopathy (0.4%), mild non-prolif-
erative diabetic retinopathy (5.2%) and moderate non-prolifer-
ativediabetic retinopathy (29.4%).TheUKProspectiveDiabetes
Study (UKPDS) reported similar 6-year incidence of diabetic
retinopathy: 22% [74]. However, the UKPDS population were
studied from a later time point: clinical diagnosis of diabetes. In
the Wisconsin Epidemiological Study of Diabetic Retinopathy
(WESDR) 4-year progression of diabetic retinopathy and pro-
gression to proliferative diabetic retinopathy was observed in
41.2 and10.5%of subjectswithType I diabetes, 34and7.4%of
insulin-treated patientswithType 2 diabetes and 24.9 and 2.3%
of non-insulin treated patients, respectively [75].
Impact of diabetic retinopathy on vision
Estimates of the proportion of African patients with diabetes
who are visually impaired are high even compared with older
European and American studies. Of subjects in the Diabetes in
Egypt project [41], 7.3% had best-corrected visual acuity in
the better eye < 6 ⁄60. In contrast, of the population in the
Wisconsin Epidemiological Study of Diabetic Retinopathy,
3.6% of patients aged < 30 years at diagnosis, and 1.6% of
patients aged ‡ 30 years at diagnosis were legally blind
according to US standards [76,77]. The World Health
Organization estimates that, in the USA and Canada, 17% of
blindness is attributable to diabetic retinopathy [78]. While
data are sparse, the proportion of visual impairment and
blindness as a result of diabetic retinopathy in Africa appears to
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be considerably less. However, the prevalence of visual
impairment and blindness is significantly higher in Africa [78],
reflecting high prevalence of pathologies including uncorrected
refractive error, cataract, corneal opacities and glaucoma.
The findings of this review have important implications for
both research and clinical practice. Large, community-based
cross-sectional and cohort studies are needed to investigate
rates and determinants of diabetic retinopathy prevalence,
incidence and progression across Africa. Consensus is needed
on standardized data sets and the most appropriate methods of
identification and classification of diabetic retinopathy in
Africa. In Europe and America, there is strong evidence for the
role of poor glycaemic control and co-pathology, including
hypertension in development and progression of diabetic reti-
nopathy. Similarly, a strong evidence base exists for the treat-
ment of sight-threatening diabetic retinopathy with laser photo-
coagulation and intravitreal agents. This evidence has yet to be
accrued in African settings. Management of systemic disease
and screening and treatment of retinopathy requires substantial
infrastructure, which is currently lacking in many African
states. The public health and health economic challenges for
policymakers across Africa are significant.
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